BeiGene CEO, John Oyler, has announced the opening of a new 42-acre innovation center in Hopewell, New Jersey, which is the culmination of a three-year project costing $800mn, as it expands the Company’s integrated manufacturing and research and development footprint in the U.S. The new facility will expand its biologics manufacturing and R&D capabilities - providing a production capacity of two million vials per year - as the company looks to explore new biologics partnerships and accelerate product launches, such as the PD-1 inhibitor Tevimbra.

Eurofins CDMO Alphora Inc. - has expanded its API capacity with a new manufacturing facility in Mississauga, Canada, as the company looks to better serve their growing client base and address increasing demand for life-saving therapies from Phase 1 to commercialization. The 15,000 sq.-ft. facility enhances the company’s existing capabilities with additional GMP processing and warehousing space that will support API batches up to 125 and handling of Safebridge Class 3 compounds.

South Korean CDMO, Lotte Biologics, has acquired land in Songdo, South Korea, to construct three biomanufacturing plants to increase production capacity to 360,000L, and in the process is expected to create 37,000 jobs.

CordenPharma has announced that it is investing €900 mn (c.$982 mn) over the next three years to expand its peptide manufacturing capacity in the U.S. and Europe, driven by rising demand for GLP-1 drugs. The Swiss CDMO plans to build a third facility and add new manufacturing lines to its Boulder, Colorado site, and construct a new large-scale manufacturing facility elsewhere in Europe.

A recently published report from Future Market Insights highlights significant potential for global CMO/CDMO market growth; with projections suggesting a significant increase in value from $22.5 bn in 2023 to $39.4 bn by 2033.

Bora Pharmaceuticals, the Taiwan listed CDMO with a growing U.S. network, has announced an agreement to acquire Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland.

Since breaking ground in October 2022 and fresh from its IPO in September 2023, SCHOTT Pharma, the maker of drug containment solutions and delivery systems for injectable drugs, announced the culmination of a EUR 76 million investment with the opening of its new production facility in Lukácsháza, Hungary.

A new report suggests that the global sterile injectable CDMO market is projected to reach $33.7 bn by 2034, driven by high demand for biologics, accelerated development timelines, and the shift towards end-to-end business models offering comprehensive services from API development to drug manufacturing.

Simtra BioPharma Solutions, the new name for Baxter International’s BioPharma Solutions (BPS), announced last week that work had started on constructing a 150,000 square foot extension to its facility in Bloomington, Indiana.

Despite its parent company facing scrutiny and potential sanctions from the U.S. government, WuXi AppTec continues to expand its contract research, development and manufacturing organization (CRDMO) services in its native China.

Reflecting Singapore's growing status as a hub for Asia’s biopharmaceutical industry, Novartis has announced a $256 million expansion of its antibody manufacturing facility on the Malay peninsula.

Adare Pharma Solutions, the global CDMO specializing in oral dosage forms, announced it will enhance its facility in Milan, Italy.

Firefly Bio has launched with $94 million in Series A funding, introducing a novel platform utilizing degrader antibody conjugates (DACs) aimed at cancer treatment.

BioAge Labs has raised $170 million in Series D funding to enhance therapies for obesity and metabolic diseases. The round was led by Sofinnova Investments with participation from both new and existing investors. 

Alys Pharmaceuticals, a novel developer of skin medications, has been established following the merger of six biotech startups, supported by a $100 million from Medicxi, a European life sciences investment firm.

Catalent has been the main supplier of fill-finish and packaging services for Novo Nordisk’s Glucagon-like peptide-1 (GLP-1) syringes and injection pens, and the deal will see the sale of Catalent’s fill-finish sites in Italy, Belgium and Bloomington in the U.S. sold to Novo Nordisk, expanding its in-house manufacturing capabilities of weight loss and obesity-targeting drugs.

IGC Pharma is progressing towards a Phase 1 clinical trial for its proprietary Alzheimer's drug candidate, IGC-AD1, after demonstrating promising preclinical results.

French clinical-stage biotechnology company Vivet Therapeutics has been granted $5.3 million through the France Health Innovation Plan 2030 to support the company's pioneering work in gene therapy.

Global pharmaceutical company, Teva Pharmaceutical, has announced plans to divest its API business, aligning with its 'Pivot to Growth' strategy. This move aims to reduce complexity and enhance profitability, whilst enabling them to focus on streamlining operations and focusing on core capabilities in generics, specialty medicines, and biopharmaceuticals.

Upperton Pharma Solutions announced a significant expansion into sterile drug manufacturing with the launch of a new c. $6.3 million GMP facility.